Last Updated on December 31, 2023 by The Health Master
Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), desvenlafaxine extended-release tablets, 25 mg to market.
This is a generic equivalent of Pristiq extended-release tablets, 25 mg of PF PRISM C.V. The product will be manufactured at Lupin’s facility in Goa, India.
Desvenlafaxine extended-release tablets, 25 mg (RLD Pristiq) had estimated annual sales of US$ 14 million in the US (IQVIA MAT December 2021)
USFDA authorises first C-19 diagnostic test using breath samples
USFDA gives approval to Aleor for Lidocaine & Prilocaine cream
USFDA gives nod to Indoco Remedies for Lacosamide injection
USFDA gives tentative approval to Alembic for generic Pradaxa capsules
USFDA approves Cell Therapy for earlier lymphoma
USFDA approves Ozempic 2 mg to treat Type-II Diabetes
Drug recall: Insulin Glargine recalled due to this reason
DCGI: Fourfold increase in Investigational New Drugs Applications in India
4 Medical Devices Parks to come up in a total of 1,326 acres
CDSCO Committee gives approval to Sun Pharma for Ranibizumab
E-Cigarettes using synthetic nicotine come under FDA oversight
USFDA authorises first C-19 diagnostic test using breath samples
Govt wants to ease compliance burden on Pharma Industry
FDA Maharashtra issues show cause notices to 95 Pharma units
NPPA fixes retail price of 23 formulations: April 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
